ClinicalTrials.gg
RecruitingNCT07856381Updated Oct 2, 2026

Understanding Lifespan Trajectories of Social Cognition, Brain Microstructure and Iron Dysregulation in Schizophrenia

An observational study in Healthy Control Subjects and Schizophrenia Diagnosis, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Medical University Innsbruck · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Schizophrenia with a site in Austria — 4 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Austria.

Started
2026
with 1 other
Observational
2 of 35
1 open now
Registered
35th of 35
by date
Lead sponsor
2 of 35
Medical University Innsbruck

Among the 35 studies in Schizophrenia with a site in Austria, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 35th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 35 studies in Schizophrenia with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Schizophrenia with a site in Austria, or all of them as a file.
02

Study summary

This study aims to better understand how schizophrenia may affect social thinking, emotion regulation, brain function, and biological processes over time.

Two groups will take part in the study:

  1. people diagnosed with schizophrenia
  2. healthy adults without schizophrenia

Participants in both groups will complete a series of behavioral tasks and questionnaires. These will assess abilities such as understanding other people, processing social information, and regulating emotions. For participants with schizophrenia, we will also assess clinical symptoms and their severity.

The study includes three assessment visits:

  1. Baseline: at the beginning of the study
  2. 12-month follow-up: approximately one year later
  3. 24-month follow-up: approximately two years later

At all three visits, participants will complete behavioral tests and questionnaires, and blood and hair samples will be collected. These samples may help researchers investigate biological factors that are related to mental health, stress, and changes over time.

Participants will also undergo an MRI brain scan at the baseline visit and again at the 12-month follow-up.

People with schizophrenia may experience changes in thinking, emotions, social functioning, physical health, and brain function across adulthood. However, we still do not fully understand how these changes develop over time or how they differ from normal aging.

By comparing people with schizophrenia with healthy adults of different ages and following them over time, we can study possible differences in aging trajectories. This means examining whether certain abilities, symptoms, biological markers, or brain characteristics change differently with age in people with schizophrenia.

The study uses an accelerated longitudinal design. Instead of following one group of people for many decades, researchers recruit participants from different age groups and follow them for a shorter period. Combining information across these age groups can help researchers estimate longer-term patterns of change.

03

Conditions studied

  • Healthy Control Subjects
  • Schizophrenia Diagnosis

Keywords

  • schizophrenia
  • social cognition
  • Brain iron
  • accelerated longitudinal design
  • age trajectory
  • lifespan
  • Cognitive Dysfunction
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Quantitative Susceptibility Mapping
  • Extracellular Vesicles
  • Oxidative Stress
  • Redox Regulation
  • Glutathione
  • Hair Proteomics
  • Psychosocial Functioning
  • Negative Symptoms
  • Theory of Mind
  • Emotion Recognition
  • Emotion Regulation
  • Attributional Style
  • NDEV
  • functional outcome
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants with SZ will be recruited through multiple clinical pathways to ensure adequate sample size and representativeness across the adult lifespan. The primary recruitment source is the specialized outpatient clinic for SZ spectrum disorders at the Department of Psychiatry, MUI, which serves a large catchment area and maintains detailed diagnostic records. Additional participants will be recruited through a collaborating psychiatric hospital and office-based psychiatrists and psychosocial service providers in the region, with whom the Dep. of Psychiatry maintains established referral networks. Patients in the SZ group must have a DSM-5 diagnosis of schizophrenia confirmed by their treating psychiatrist. HC participants will be recruited through advertisements in online platforms, social media, and community outreach.

Eligibility criteria

Inclusion criteria (all participants):

age 18-70 years at baseline; normal or corrected-to-normal vision; sufficient hearing; fluency in German; willingness and ability to understand and comply with study procedures. Participants must either be healthy adults without any mental health disorder (HC) or have a confirmed diagnosis of SZ.

Inclusion criteria (SZ only):

clinical stability at assessment, defined as no change in psychopathological symptoms and no modification of pharmacotherapy for at least three months prior to study entry, as confirmed by the treating psychiatrist; full remission is not required.

Exclusion criteria (all participants):

incapacity to consent; current or lifetime history of brain surgery or epilepsy; MRI (unremovable metal parts in the upper body, active implants, claustrophobia); current or past substance abuse disorder (excluding caffeine and nicotine); pregnancy.

Exclusion criteria (HC only):

any current or lifetime Axis I psychiatric disorder; first-degree relative with an Axis I disorder; any neurological disorder or other mental health condition; current or past use of psychotropic medication.

Additional Eligibility Criteria for Cycle-Timed Neuroimaging:

To minimize hormonal confounding of emotion-regulation-related neural measures, menstruating female participants will be scanned in the early follicular phase (cycle days 1-6), requiring regular menstrual cycles (21-35 days) and a negative pregnancy test at relevant visits.

Use of hormonal will be recorded.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Schizophrenia Group

    Group of people with a diagnosis of schizophrenia confirmed by their treating psychiatrist.

  • Healthy control group

    Group absent of any Axis-I Diagnosis

06

What researchers measure

Primary outcomes

  1. Change in Theory of Mind performance

    Theory of Mind will be assessed using the EmpaToM task. The outcome will include performance-based indices of cognitive and affective Theory of Mind. Higher scores indicate better ability to infer and understand the mental states of others.

    Time frame: Baseline, 12 months, and 24 months

  2. Change in attributional style

    Attributional style will be assessed using the Internal, Personal and Situational Attributions Questionnaire-Revised. The outcome will measure tendencies to attribute positive and negative social events to internal, personal-external, or situational-external causes; aswell as monocausal-inference-style.

    Time frame: Baseline, 12 months, and 24 months

  3. Change in emotion recognition performance

    Emotion recognition will be assessed using the DiagnosIS Emotion Recognition Task. The outcome will measure accuracy in identifying facial emotional expressions. Higher scores indicate better emotion recognition performance.

    Time frame: Baseline, 12 months, and 24 months

  4. Change in Emotion Regulation Choice

    The Emotion Regulation Choice Task is a behavioral paradigm used to examines whether individuals adapt their choice of emotion regulation strategy according to the intensity of negative emotional stimuli. It will be used to assess the change in the degree to which strategy choice changes as a function of emotional intensity.

    Time frame: Baseline, 12 months, 24 months

Secondary outcomes

  1. Change in reflective functioning

    Reflective functioning will be assessed using the Reflective Functioning Questionnaire. The outcome will measure certainty and uncertainty about mental states. Scores will be analyzed according to the scoring rules of the instrument.

    Time frame: Baseline, 12 months, and 24 months

  2. Change in self reported Emotion Regulation

    Self reported emotion regulation will be assessed using the Emotion Regulation Questionnaire (ERQ). The ERQ is a 10-item self-report measure assessing the habitual use of two emotion-regulation strategies: cognitive reappraisal and expressive suppression.

    Time frame: Baseline, 12 months, 24 months

  3. Change in global cognitive functioning

    Global cognition will be assessed using the Screen for Cognitive Impairment in Psychiatry. The outcome will provide a standardized measure of cognitive functioning across domains including verbal learning, working memory, verbal fluency, and processing speed. Higher scores indicate better cognitive performance.

    Time frame: Baseline, 12 months, and 24 months

  4. Change in daily functioning and disability

    Daily functioning and disability will be assessed using the World Health Organization Disability Assessment Schedule 2.0. The outcome will measure functioning across cognition, mobility, self-care, interpersonal relationships, life activities, and participation in society. Higher scores indicate greater disability.

    Time frame: Baseline, 12 months, and 24 months

  5. Change in brain iron distribution measured by quantitative susceptibility mapping

    Brain iron distribution will be assessed using quantitative susceptibility mapping (QSM) derived from multi-echo gradient echo MRI.

    Time frame: Baseline and 12 months

  6. Change in R2* relaxometry measures of brain iron-sensitive signal

    R2\* values will be derived from multi-echo gradient echo MRI as an iron-sensitive neuroimaging measure.

    Time frame: Baseline and 12 months

  7. Change in white matter microstructure

    White matter microstructure will be assessed using diffusion-weighted MRI. Outcomes will include fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity.

    Time frame: Baseline and 12 months

  8. Change in resting-state functional connectivity

    Resting-state functional connectivity will be assessed using resting-state functional MRI.

    Time frame: Baseline and 12 months

  9. Change in extracellular vesicle-derived redox markers

    Neuronally derived extracellular vesicles will be isolated from plasma samples.

    Time frame: Baseline, 12 months, and 24 months

  10. Change in hair proteomic signatures

    Hair samples will be analyzed using untargeted proteomic profiling. Outcomes will include proteomic signature related to oxidative stress, antioxidant defense, inflammation, mitochondrial bioenergetics, systemic stress, and biological aging.

    Time frame: Baseline, 12 months, and 24 months

  11. Change in hair cortisol concentration

    Hair cortisol concentration will be measured from scalp hair samples as an index of cumulative hypothalamic-pituitary-adrenal axis activity over the preceding months. Higher values indicate higher cumulative cortisol exposure.

    Time frame: Baseline, 12 months, and 24 months

  12. Change in psychopathological symptom severity

    Psychopathological symptoms in participants with schizophrenia will be assessed using the Positive and Negative Syndrome Scale. The outcome will include total and subscale scores for positive symptoms, negative symptoms, and general psychopathology. Higher scores indicate greater symptom severity.

    Time frame: Baseline, 12 months, and 24 months

  13. Change in negative symptom severity

    Negative symptoms will be assessed using the Brief Negative Symptom Scale. The outcome will measure negative symptom domains including anhedonia, asociality, avolition, blunted affect, and alogia. Higher scores indicate greater negative symptom severity.

    Time frame: Baseline, 12 months, and 24 months

07

Study locations

1 of 1 sites recruiting
  • Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology; Medical University of Innsbruck
    Innsbruck, Tyrol 6020, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2030, 48 months after the start.

Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's planned 48 months is close to that.

Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 2, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 2030
CompletionEst.
Sep 30, 2030
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856381
Collaborators
Technische Universität Dresden, University of Innsbruck, Austria
Responsible party
Beatrice Frajo-Apor (M.D., PhD., Medical University Innsbruck) — Principal investigator
First posted
Oct 2, 2026
Start date
Sep 1, 2026
Primary completion
Sep 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Oct 2, 2026

Study contacts

Christopher Schaar, M.Sc.
Contact
christopher.schaar@i-med.ac.at
0043 512 9003 81298

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion